News
Latest news: Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform
Access Press Release
Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome to Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Our services
At Quotient Sciences, we’ve streamlined the drug development process by providing pre-formulation screening, formulation development, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO, allowing us to support drug programs from candidate selection through commercial supply.
Our latest updates
Discover what’s happening at Quotient Sciences
-
Thought LeadershipMark Egerton featured in Pharma's Almanac roundtable article: What important company milestone do you anticipate reaching in 2022?In this roundtable with Pharma's Almanac, Mark Egerton, CEO of Quotient Sciences, answers the Question 'What important company milestone do you anticipate reaching in 2022?'
-
Jun 15SeminarBIO International 2022 Happy Hour Seminar: Moving Drug Substance Off the Critical PathSave your spot at our BIO happy hour seminar on June 15, "Moving Drug Substance Off the Critical Path- Streamlined Strategies to Accelerate to First-in-Human & Beyond."
-
WebinarMoving Drug Substance Off the Critical Path — Streamlined Strategies to Accelerate to First-in-Human & BeyondJoin Quotient’s Director of Drug Development Consulting, Dr Stephen McQuaker Vice President of Bioanalysis, Dr Stuart McDougall, as he explores case studies to demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise to get drug substance off the critical path.
-
Thought LeadershipPharma's Almanac - Mark Egerton - Q: What’s the key to being a leader in the industry?Mark Egerton, CEO of Quotient Sciences was recently asked to contribute to a piece with Pharma's Almanac, entitled 'What’s the key to being a leader in the industry?'
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.